

Supplementary Table S1 Quality assurance of included studies

First Author (Year)	Source	Quality of case report					
		Documentation	Uniqueness	Educational value	Objectivity	Interpretation	Total
Chen (2023)	<i>Front. Oncol</i>	2	1	1	2	2	8
Evin (2022)	<i>Diagnostics (Basel)</i>	1	1	2	2	2	8
Lin (2021)	<i>Am J Case Rep</i>	1	1	2	2	2	8
Nakai (2023)	<i>Respir Med Case Rep</i>	2	1	2	2	2	9
Qiu (2022)	<i>Transl Lung Cancer Res</i>	2	2	2	2	2	10
Sahin (2023)	<i>J Oncol Pharm Pract</i>	2	1	1	2	2	8
Moss (2023)	<i>Front. Immunol</i>	2	1	2	2	2	9
Wang (2023)	<i>Invest New Drug</i>	2	2	2	2	2	10
Wen (2022)	<i>Medicine (Baltimore)</i>	1	2	2	2	2	9
Zhang (2023)	<i>Clin Cosmet Investig Dermatol</i>	2	2	2	2	2	10
DeMaio (2022)	<i>JAAD Case Rep</i>	2	1	2	2	2	9
Raibagkar (2020)	<i>J Neuroimmunol</i>	2	2	2	2	2	10
Zhu (2019)	<i>Onco Targets Ther</i>	1	2	1	1	2	7
Liang (2019)	<i>Front. Oncol</i>	1	2	2	2	2	9
Farid (2020)	<i>Cureus</i>	2	2	2	2	2	10
Mavrotas (2020)	<i>Prog Neurol Psychiatry</i>	2	1	1	2	2	8
Sirgiovanni (2021)	<i>Thorac Cancer</i>	2	2	2	2	2	10
Valecha (2019)	<i>J Oncol Pharm Pract</i>	2	2	2	2	2	10
Williams (2016)	<i>JAMA Neurol</i>	2	2	2	2	2	10
Sun (2018)	<i>J Immunother</i>	2	2	2	2	2	10
Liu (2022)	<i>Transl Oncol</i>	2	1	1	2	1	7
Li (2021)	<i>Thorac Cancer</i>	2	2	2	2	2	10
Chen (2022)	<i>Transl Cancer Res</i>	2	2	2	2	2	10
Qu (2021)	<i>Ann Palliat Med</i>	2	1	2	2	2	9

Listed by immune-checkpoint inhibitors, and within each agent, listed in alphabetical order of the first author's name.